Electromed, Inc. Announces Fiscal 2020 Fourth Quarter and Full Year Financial Results

Nachrichtenquelle: Business Wire (engl.)
25.08.2020, 22:05  |  104   |   |   

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended June 30, 2020 (“Q4 FY 2020”).

Q4 FY 2020 Highlights

  • Net revenue decreased 20.1% to $6.9 million, from $8.6 million for the three months ended June 30, 2019 (“Q4 FY 2019”), primarily due to industrywide disruption from the COVID-19 pandemic.
  • Operating income, which included $0.9 million of government stimulus income from the Provider Relief Fund established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), totaled $1.3 million, compared to $1.5 million in Q4 FY 2019.
  • Net income was $1.3 million, or $0.15 per diluted share, compared to $1.1 million, or $0.13 per diluted share, in Q4 FY 2019.
  • Cash as of June 30, 2020 was $10.5 million benefiting from $1.3 million in operating cash flow in Q4 FY 2020.

FY 2020 Highlights

  • Net revenue increased 3.7% to $32.5 million from $31.3 million during the fiscal year ended June 30, 2019 (“FY 2019”).
  • Operating income grew 80.9% to $5.1 million, from $2.8 million in FY 2019.
  • Net income rose 110.1% to $4.2 million, or $0.47 per diluted share, from $2.0 million, or $0.23 per diluted share, in FY 2019.
  • Cash increased by $2.7 million during fiscal 2020, benefitting from $4.2 million in operating cash flow.

Kathleen Skarvan, President and Chief Executive Officer of Electromed, commented, “In fiscal 2020 we delivered revenue growth and record profitability, despite a challenging fourth quarter during which the COVID-19 pandemic significantly impacted our operating and financial results. Encouragingly, our home care referrals approached pre-COVID-19 levels as we exited the fourth quarter, in tandem with an uptick in the reopening of physician offices and related activities. I commend our entire Electromed team for their unwavering commitment to ensuring seamless manufacturing and delivery of SmartVest Airway Clearance during these challenging times.”

Ms. Skarvan continued, “We expect continued uncertainty surrounding COVID-19 through fiscal 2021 that will continue to impact our financial and operational results. We believe we have a strong balance sheet and an extremely dedicated team, which will enable us to withstand this pandemic and pursue a greater share of the large, underpenetrated bronchiectasis market. Our priority continues to be the health, safety and wellbeing of our teammates, clinicians and patients, while executing on our organic growth strategy. With this in mind, we plan to continue investing in our business, serving patients by balancing virtual and in-person visits, and providing best-in-class customer service and delivering our differentiated SmartVest Airway Clearance devices to drive long-term profitable growth.”

Q4 FY 2020 Review

Net revenue in Q4 FY 2020 decreased 20.1% to $6.9 million, from $8.6 million in Q4 FY 2019, primarily driven by lower home care revenue. Home care revenue declined 21.3% to $6.3 million from $8.0 million in Q4 FY 2019, primarily due to lower referrals driven by the COVID-19 pandemic. Field sales employees totaled 44, of which 37 were direct sales, at the end of Q4 FY 2020, compared to 40 at the end of Q4 FY 2019, of which 34 were direct sales. Annualized home care revenue was $678,000 per direct field sales employee, below our target productivity range of $750,000 - $850,000 due to the revenue decline associated with the COVID-19 pandemic. Institutional revenue decreased 25.9% to $273,000 from $368,000 in Q4 FY 2019, primarily due to a decrease in volume of devices and garments sold.

Gross profit in Q4 FY 2020 decreased 16.2% to $5.6 million, or 81.3% of net revenue, from $6.7 million, or 77.5% of net revenue, in Q4 FY 2019. The decrease in gross profit dollars was primarily due to the decrease in home care revenue driven by the COVID-19 pandemic. The increase in gross profit percentage was due to a higher mix of Medicare patients, in-sourcing of patient training activity and reduced warranty costs.

Selling, general and administrative (“SG&A”) expenses in Q4 FY 2020 decreased by $277,000 to $4.8 million from $5.1 million in Q4 FY 2019. The decline in SG&A spending was primarily due to lower incentive payments driven by lower home care revenue and reductions in travel expenses related to the COVID-19 pandemic. As a percentage of revenue, SG&A expenses were 69.7% compared to 59.0% in the same period in the prior year. Research and development expenses increased to $415,000 from $107,000 in Q4 FY 2019, in connection with the development of a next generation device. As a partial offset to our core operating expenses, we received and recognized $0.9 million of government stimulus from the Provider Relief Fund established under the CARES Act which is intended to offset losses in revenue and expenses Medicare fee-for-service providers incurred due to the impacts of the COVID-19 pandemic.

Operating income totaled $1.3 million, compared to $1.5 million in Q4 FY 2019.

Net income before income taxes totaled $1.3 million compared to $1.5 million in Q4 FY 2019.

Net income was $1.3 million, or $0.15 per diluted share, compared to $1.1 million, or $0.13 per diluted share, in Q4 FY 2019. In Q4 FY 2020, income tax benefit totaled $9,000, compared to an income tax expense of $432,000 in the same period of the prior year. During Q4 FY 2020, a discrete tax benefit of $343,000 was recognized as a result of the exercise of outstanding stock options.

FY 2020 Summary

For the fiscal year ended June 30, 2020, revenue grew 3.7% to $32.5 million, from $31.3 million in fiscal 2019, driven by $430,000 of incremental distributor revenue, a 24.7% increase in institutional revenue, and a 1.3% increase in home care revenue. Gross margins were 77.6%, compared to 76.2% in the prior fiscal year, while net income was $4.2 million, or $0.47 per diluted share, compared to $2.0 million, or $0.23 per diluted share, in fiscal 2019. The Company’s cash increased by $2.7 million, driven by $4.2 million of operating cash flow.

Financial Condition

The Company’s balance sheet at June 30, 2020 included cash of $10.5 million, accounts receivable of $12.9 million, no debt, working capital of $25.0 million, and shareholders’ equity of $30.2 million.

Conference Call

Management will host a conference call on Tuesday, August 25, 2020 at 4:00 pm CT (5:00 pm ET) to discuss Q4 FY 2020 financial results and other matters.

Interested parties may participate in the call by dialing:

  • (877) 407-9753 (Domestic)
  • (201) 493-6739 (International)

The conference call also will be accessible via the following link: https://78449.themediaframe.com/dataconf/productusers/elctr/mediaframe ...

For those who cannot listen to the live broadcast, an online webcast replay will be available in the Investor Relations section of the Company’s web site at: http://investors.smartvest.com/

About Electromed, Inc.

Electromed, Inc. manufactures, makes, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992. Further information about the Company can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the duration, extent and severity of the COVID-19 pandemic, including its effects on our business, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Electromed, Inc.

Condensed Balance Sheets

 
June 30, 2020 June 30, 2019
Assets (unaudited)
Current Assets
Cash

$

10,479,150

$

7,807,928

Accounts receivable (net of allowances for doubtful accounts of $45,000)

 

12,940,677

 

12,760,042

Contract assets

 

902,619

 

995,847

Inventories, net

 

3,084,620

 

2,622,000

Prepaid expenses and other current assets

 

353,318

 

353,214

Income taxes receivable

 

262,155

 

-

Total current assets

 

28,022,539

 

24,539,031

Property and equipment, net

 

3,788,469

 

3,604,744

Finite-life intangible assets, net

 

598,389

 

581,413

Other assets

 

80,166

 

45,044

Deferred income taxes

 

755,000

 

629,000

Total assets

$

33,244,563

$

29,399,232

 
Liabilities and Shareholders’ Equity
Current Liabilities
Current maturities of other long-term liabilities

$

72,328

$

30,320

Accounts payable

 

555,510

 

586,575

Accrued compensation

 

1,404,497

 

1,404,662

Income taxes payable

 

-

 

288,511

Warranty reserve

 

740,000

 

810,000

Other accrued liabilities

 

214,045

 

530,453

Total current liabilities

 

2,986,380

 

3,650,521

Other long-term liabilities

 

8,868

 

14,737

Total liabilities

 

2,995,248

 

3,665,258

 
Commitments and Contingencies
 
Shareholders' Equity
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,567,834 and 8,408,351 issued and outstanding at June 30, 2020 and June 30, 2019, respectively

 

85,678

 

84,084

Additional paid-in capital

 

16,480,134

 

16,127,826

Retained earnings

 

13,683,503

 

9,522,064

Total shareholders’ equity

 

30,249,315

 

25,733,974

Total liabilities and shareholders’ equity

$

33,244,563

$

29,399,232

 

Electromed, Inc.

Condensed Statements of Operations

 
For the Three Months Ended
June 30,
For the Twelve Months Ended
June 30,

 

2020

 

 

2019

 

2020

 

 

2019

(unaudited)

(unaudited)

(unaudited)

Net revenues

$

6,877,351

 

$

8,603,602

$

32,470,688

 

$

31,299,750

Cost of revenues

 

1,288,711

 

 

1,935,289

 

7,270,642

 

 

7,451,806

Gross profit

 

5,588,640

 

 

6,668,313

 

25,200,046

 

 

23,847,944

 
Operating expenses (income)
Selling, general and administrative

 

4,796,507

 

 

5,073,421

 

19,944,851

 

 

20,435,010

Research and development

 

415,236

 

 

106,526

 

1,049,612

 

 

583,311

Government stimulus income

 

(913,108

)

 

-

 

(913,108

)

 

-

Total operating expenses

 

4,298,635

 

 

5,179,947

 

20,081,355

 

 

21,018,321

Operating income

 

1,290,005

 

 

1,488,366

 

5,118,691

 

 

2,829,623

 
Interest income, net

 

9,547

 

 

33,359

 

120,748

 

 

90,707

Net income before income taxes

 

1,299,552

 

 

1,521,725

 

5,239,439

 

 

2,920,330

 
Income tax expense (benefit)

 

(9,000

)

 

432,000

 

1,078,000

 

 

940,000

Net income

$

1,308,552

 

$

1,089,725

$

4,161,439

 

$

1,980,330

 
Income per share:
Basic

$

0.15

 

$

0.13

$

0.50

 

$

0.24

Diluted

$

0.15

 

$

0.13

$

0.47

 

$

0.23

 
 
Weighted-average common shares outstanding:

Basic

8,443,954

8,341,684

8,403,220

8,306,338

Diluted

 

8,968,800

 

 

8,615,207

 

8,826,418

 

 

8,631,469

Electromed, Inc.

Condensed Statements of Cash Flows

 
Twelve Months Ended June 30,

 

2020

 

 

2019

 

Cash Flows From Operating Activities (unaudited)
Net income

$

4,161,439

 

$

1,980,330

 

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation

 

616,468

 

 

804,587

 

Amortization of finite-life intangible assets

 

121,762

 

 

120,640

 

Amortization of debt issuance costs

 

-

 

 

1,958

 

Share-based compensation expense

901,932

924,071

 
Deferred taxes

 

(126,000

)

 

(265,000

)

Loss on disposal of property and equipment

 

2,622

 

 

11,186

 

Loss on disposal of intangible assets

 

-

 

 

4,840

 

Changes in operating assets and liabilities:
Accounts receivable

 

(180,635

)

 

(948,734

)

Contract assets

 

93,228

 

 

(219,509

)

Inventories

 

(449,335

)

 

(106,174

)

Prepaid expenses and other assets

 

78,222

 

 

591,457

 

Income tax receivable

 

(262,155

)

 

-

 

Income tax payable

 

(288,511

)

 

(108,879

)

Accounts payable and accrued liabilities

 

(472,589

)

 

(200,899

)

Net cash provided by operating activities

 

4,196,448

 

 

2,589,874

 

 
Cash Flows From Investing Activities
Expenditures for property and equipment

 

(844,226

)

 

(1,330,598

)

Proceeds from sales of equipment

 

-

 

 

1,750

 

Expenditures for finite-life intangible assets

 

(132,970

)

 

(57,790

)

Net cash used in investing activities

 

(977,196

)

 

(1,386,638

)

 
Cash Flows From Financing Activities
Principal payments on long-term debt including capital lease obligations

 

-

 

 

(1,103,001

)

Issuance of common stock upon exercise of options

 

80,369

 

 

251,849

 

Taxes paid on stock options exercised on a net basis

 

(628,399

)

 

-

 

Net cash used in financing activities

 

(548,030

)

 

(851,152

)

Net increase in cash

 

2,671,222

 

 

352,084

 

Cash
Beginning of period

 

7,807,928

 

 

7,455,844

 

End of period

$

10,479,150

 

$

7,807,928

 

 

Electromed Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel